Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10681465 | 1.00 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL10504563 | 1.00 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL6734265 | 1.00 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL6734147 | 1.00 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB | |
| Hydrochloric Acid SCHEMBL14742972 | 0.98 | LTA4H (0.37) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL2948327 | 0.90 | ALOX15 (0.35) | HRH3HRH2HRH1 | |
| SCHEMBL2210788 | 0.86 | HRH3 (0.40) | HRH3HRH2HRH1MAOB | |
| SCHEMBL10505725 | 0.86 | HRH3 (0.40) | HRH3HRH2HRH1MAOB | |
| SCHEMBL10505714 | 0.86 | HRH3 (0.40) | HRH3HRH2HRH1MAOB | |
| SCHEMBL2110831 | 0.86 | HRH3 (0.40) | HRH3HRH2HRH1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| CN-116802184-A | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | 埃科特莱茵药品有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2023-04-18 | — | — | US | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3390389-B1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2021-05-19 | — | — | EP | disclosed |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-4582909-A | Benzobicyclic lactam acids and derivatives as cognition activators | WARNER-LAMBERT COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| US-4582838-A | FOR TREATING SENILITY OR REVERSING EFFECTS OF ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA | WARNER-LAMBERT COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0174136-A1 | Derivatives of dihydro-1H-pyrrolo(1,2-c)imidazol-3,5-dione as cognition activators | WARNER-LAMBERT COMPANY (US) | 1986-03-12 | — | — | EP | disclosed |
| US-4558155-A | N-(Aryloxyalkyl)-N'-(aminoalkyl)thioureas | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| EP-0160436-A2 | N-[(Amino)Alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulphur linked substitution in the 2, 3 or 4-position | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-11-06 | — | — | EP | disclosed |
| EP-0151539-A2 | Benzobicyclic lactam acids, their derivatives, an intermediate in the preparation thereof and processes for the production thereof | WARNER-LAMBERT COMPANY (US) | 1985-08-14 | — | — | EP | disclosed |
| EP-0151541-A2 | Saturated bicyclic lactam acids, their derivatives, a process for preparing the compounds and a pharmaceutical composition comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-14 | — | — | EP | disclosed |
| US-4500529-A | ANTIARRHYTHMIA AGENT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-02-19 | — | — | US | disclosed |
| US-4476308-A | 1-Pyrrolidine acetamides | HOFFMANN-LA ROCHE INC. (US) | 1984-10-09 | — | — | US | disclosed |
| US-4145347-A | TREATMENT OF SENILITY, AMNESIA AND LEARNING DISORDERS | PARKE, DAVIS & COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | LTA4H 2227/4885HRH3 457/4885HRH2 217/4885 |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | LTA4H 2227/4885HRH3 457/4885HRH2 217/4885 |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | LTA4H 2248/4885HRH3 495/4885HRH2 227/4885 |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | PDGFRA, PDGFRB, ABL1 | LTA4H 2695/4885HRH3 1593/4885HRH2 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.